Skip to content

Efficacy and Mechanism of Siji Decoction in the Topical Treatment of Scalp Seborrheic Dermatitis with Blood-heat and Wind-dryness Syndrome

Efficacy and Mechanism of Siji Decoction in the Topical Treatment of Scalp Seborrheic Dermatitis with Blood-heat and Wind-dryness Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001542
Enrollment
Unknown
Registered
2026-06-20
Start date
2023-09-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scalp Seborrheic Dermatitis

Interventions

Siji decoction group:The Siji decoction is a 60g dosage of a traditional Chinese medicine powder, in an external use form. The ingredients in the formula are: Scutellaria baicalensis 15g, Portulaca ol
placebo group:The simulant is a Chinese medicine granule simulant of 60g. It is an external formulation prepared from 5% test group drug (Siji decoction Granules), maltodextrin, and food coloring. The

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Age range: 20 - 50 years old; (2) Meets the Western medicine diagnostic criteria for seborrheic dermatitis of the scalp, the traditional Chinese medicine diagnostic criteria, and the syndrome differentiation and classification criteria of excessive heat and dryness of the blood; (3) Has signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Have other skin disorders on the head, such as scalp psoriasis, scalp eczema, etc.; (2) Have taken oral medications (such as antibiotics, hormones, traditional Chinese medicine, etc.) or undergone physical therapy for treating seborrheic dermatitis of the scalp within 4 weeks before treatment; or have used topical medications (such as ketoconazole lotion, dimethylsulfide lotion, hormones, traditional Chinese medicine, etc.) for treating seborrheic dermatitis of the scalp within 1 week before treatment; (3) Pregnant women, women in the early stages of pregnancy, or breastfeeding women; (4) Individuals with allergic constitution or who are allergic to the components of the test drugs in this trial; (5) Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system diseases, or patients with mental disorders.

Design outcomes

Primary

MeasureTime frame
score of skin lesion;

Secondary

MeasureTime frame
pruritus numerical rating scale;Scalpdex score ;adherent scalp flaking score;

Countries

China

Contacts

Public ContactZeng Xue

Department of Dermatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences

zengxue7912@hotmail.com13810810690

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026